Objective To detect the clinical significance of MAP1LC-3 in prostate cancer. Methods From May 2016 to February 2019, 96 patients with prostate cancer were enrolled in this study. The adjacent normal tissues were used as controls. The mRNA expression of MAP1LC-3 was detected by realtime PCR analysis. The protein expression of MAP1LC-3 was detected by immunohistochemistry stains. Results The 2-△△Ct value of MAP1LC-3 in prostate cancer tissue was（0.375±0.065）, which was higher than that of（0.116±0.024） in adjacent normal tissues(P<0.01). The AOD value of MAP1LC-3 protein in prostate cancer tissue was（0.351±0.046）, which was higher than that of（0.082±0.013） in adjacent normal tissues(P<0.01). The 2-△△Ct and AOD value MAP1LC-3 in Ⅲ and Ⅳ stage, which was higher than that in Ⅰ and Ⅱ stage(P<0.01). The 2-△△Ct and AOD value MAP1LC-3 in N1 stage,which was higher than that in N0 stage(P<0.01). The 2-△△Ct and AOD value MAP1LC-3 in Gleason scores>7,which was higher than that in Gleason scores≤7(P<0.01). The 2-△△Ct and AOD value MAP1LC-3 in PSA>20 ng/mL,which was higher than that in PSA≤20 ng/mL(P<0.01). Conclusions High expression of MAP1LC-3 may be involved in the occurrence, invasion and metastasis of prostate cancer.
